Literature DB >> 35200463

Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.

Md Habban Akhter1, Irfan Ahmad2, Mohammad Y Alshahrani2, Alhanouf I Al-Harbi3, Habibullah Khalilullah4, Obaid Afzal5, Abdulmalik S A Altamimi5, Shehla Nasar Mir Najib Ullah6, Abhijeet Ojha7, Shahid Karim8.   

Abstract

Drug instillation via a topical route is preferred since it is desirable and convenient due to the noninvasive and easy drug access to different segments of the eye for the treatment of ocular ailments. The low dose, rapid onset of action, low or no toxicity to the local tissues, and constrained systemic outreach are more prevalent in this route. The majority of ophthalmic preparations in the market are available as conventional eye drops, which rendered <5% of a drug instilled in the eye. The poor drug availability in ocular tissue may be attributed to the physiological barriers associated with the cornea, conjunctiva, lachrymal drainage, tear turnover, blood-retinal barrier, enzymatic drug degradation, and reflex action, thus impeding deeper drug penetration in the ocular cavity, including the posterior segment. The static barriers in the eye are composed of the sclera, cornea, retina, and blood-retinal barrier, whereas the dynamic barriers, referred to as the conjunctival and choroidal blood flow, tear dilution, and lymphatic clearance, critically impact the bioavailability of drugs. To circumvent such barriers, the rational design of the ocular therapeutic system indeed required enriching the drug holding time and the deeper permeation of the drug, which overall improve the bioavailability of the drug in the ocular tissue. This review provides a brief insight into the structural components of the eye as well as the therapeutic challenges and current developments in the arena of the ocular therapeutic system, based on novel drug delivery systems such as nanomicelles, nanoparticles (NPs), nanosuspensions, liposomes, in situ gel, dendrimers, contact lenses, implants, and microneedles. These nanotechnology platforms generously evolved to overwhelm the troubles associated with the physiological barriers in the ocular route. The controlled-drug-formulation-based strategic approach has considerable potential to enrich drug concentration in a specific area of the eye.

Entities:  

Keywords:  drug delivery; hydrogel; implant; microneedle; nanomicelles; nanoparticles; ocular therapeutic system

Year:  2022        PMID: 35200463      PMCID: PMC8871777          DOI: 10.3390/gels8020082

Source DB:  PubMed          Journal:  Gels        ISSN: 2310-2861


  109 in total

1.  Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application.

Authors:  Soohi Patel; Chandrasekhar Garapati; Pallabita Chowdhury; Himanshu Gupta; Jerry Nesamony; Surya Nauli; Sai H S Boddu
Journal:  J Ocul Pharmacol Ther       Date:  2015-04-03       Impact factor: 2.671

2.  Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition.

Authors:  Tao Zhang; Cathie D Xiang; David Gale; Samantha Carreiro; Ellen Y Wu; Eric Y Zhang
Journal:  Drug Metab Dispos       Date:  2008-04-14       Impact factor: 3.922

Review 3.  Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.

Authors:  Hsin-Hui Shen; Elsa C Chan; Jia Hui Lee; Youn-Shen Bee; Tsung-Wu Lin; Gregory J Dusting; Guei-Sheung Liu
Journal:  Nanomedicine (Lond)       Date:  2015-06-22       Impact factor: 5.307

4.  Sustained bimatoprost release using gold nanoparticles laden contact lenses.

Authors:  Qiong Li; Cheng Ma; Yingpeng Ma; Yiping Ma; Yan Mao; Zelan Meng
Journal:  J Biomater Sci Polym Ed       Date:  2021-06-21       Impact factor: 3.517

Review 5.  A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.

Authors:  Yahya E Choonara; Viness Pillay; Michael P Danckwerts; Trevor R Carmichael; Lisa C du Toit
Journal:  J Pharm Sci       Date:  2010-05       Impact factor: 3.534

6.  Mucoadhesive dexamethasone-glycol chitosan nanoparticles for ophthalmic drug delivery.

Authors:  Ailing Yu; Hui Shi; Hui Liu; Zhishu Bao; Mali Dai; Dan Lin; Deqing Lin; Xu Xu; Xingyi Li; Yuqin Wang
Journal:  Int J Pharm       Date:  2019-12-09       Impact factor: 5.875

Review 7.  Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy.

Authors:  Md Habban Akhter; Nv Sateesh Madhav; Javed Ahmad
Journal:  Artif Cells Nanomed Biotechnol       Date:  2018-07-10       Impact factor: 5.678

8.  Multifunctional organic-inorganic hybrid nanoparticles and nanosheets based on chitosan derivative and layered double hydroxide: cellular uptake mechanism and application for topical ocular drug delivery.

Authors:  Huibo Chi; Yan Gu; Tingting Xu; Feng Cao
Journal:  Int J Nanomedicine       Date:  2017-02-28

Review 9.  Penetration Enhancers in Ocular Drug Delivery.

Authors:  Roman V Moiseev; Peter W J Morrison; Fraser Steele; Vitaliy V Khutoryanskiy
Journal:  Pharmaceutics       Date:  2019-07-09       Impact factor: 6.321

10.  Liposomes for effective drug delivery to the ocular posterior chamber.

Authors:  Sisi Lai; Yanyan Wei; Quanwu Wu; Kang Zhou; Tuo Liu; Yingfeng Zhang; Ning Jiang; Wen Xiao; Junjie Chen; Qiuhong Liu; Yang Yu
Journal:  J Nanobiotechnology       Date:  2019-05-13       Impact factor: 10.435

View more
  2 in total

Review 1.  An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Authors:  Chenchen Zhang; Yuan Yin; Jing Zhao; Yanxia Li; Yuanping Wang; Zhaoying Zhang; Lingzhi Niu; Yajuan Zheng
Journal:  Int J Nanomedicine       Date:  2022-10-19

Review 2.  Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art.

Authors:  Lidawani Lambuk; Mohd Aizuddin Mohd Lazaldin; Suhana Ahmad; Igor Iezhitsa; Renu Agarwal; Vuk Uskoković; Rohimah Mohamud
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.